ArticleCancer immunity2010
A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
Article in Cancer immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- The RNA helicase DDX53 (CAGE) contributes to RNA metabolism in a human germ cell model.bioRxiv : the preprint server for biology · 2026Article
- HDAC9 and miR-512 Regulate CAGE-Promoted Anti-Cancer Drug Resistance and Cellular Proliferation.Current issues in molecular biology · 2024Article
- Effect ofBioMed research international · 2024Article
- miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53.Journal of personalized medicine · 2023Article
- Systems-Level Mapping of Cancer Testis Antigen 1b/a to Sarcoma Pathways Identifies Activated Ran Binding-2 E3 SUMO-Protein Ligase and Transducin-Like Enhancer Protein 1.Frontiers in genetics · 2022Article
- Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering.Molecular therapy oncolytics · 2021Review
- Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance.International journal of molecular sciences · 2018Review
- Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression.Oncogene · 2018Article
- Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer.Oncotarget · 2018Article
- Dendritic Cell Therapies for Hematologic Malignancies.Molecular therapy. Methods & clinical development · 2017Review
- DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.Molecules and cells · 2017Article
- Histone demethylase lysine demethylase 5B in development and cancer.Oncotarget · 2017Review
- Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.Advances in hematology · 2017Article
- DDX53 Promotes Cancer Stem Cell-Like Properties and Autophagy.Molecules and cells · 2017Article
- miR-30a Regulates the Expression of CAGE and p53 and Regulates the Response to Anti-Cancer Drugs.Molecules and cells · 2016Article
- Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Oncotarget · 2016Article
- miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.Oncotarget · 2016Article
- Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.Iranian journal of cancer prevention · 2015Review
- Increased levels of sperm protein 17 mRNA and circulating antibodies in periampullary carcinoma patients.International journal of clinical oncology · 2015Article
- Cancer/Testis Antigen PASD1 Silences the Circadian Clock.Molecular cell · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT-PCR to analyse the mRNA expression profile of a large panel of CT genes in cell lines derived from haematological malignancies, and have studied Sp17 protein expression in the same cell lines and diffuse large B-cell lymphoma (DLBCL) biopsies. Our extensive analysis revealed multiple CT transcripts exhibiting widespread expression across cell lines derived from 21 B- and 4 T-cell malignancies. The broadest mRNA expression profiles were observed for the following eight CT genes: Sp17 (25/25), PRAME (25/25), CSAGE (24/25), PASD1 (22/25), CAGE/DDX53 (19/25), CTAGE1 (19/25), HAGE/DDX43 (16/25) and PLU-1/JARID1B (15/25). Cell lines derived from more aggressive lymphoma subtypes generally expressed CT transcripts at higher frequency. Sp17 protein was detected in a number of cell lines and in six of eleven (54.5%) DLBCL biopsies. Analysis of Sp17 protein expression, by immunohistochemistry and Western blotting, broadens the scope of this CT antigen as a potentially relevant clinical target in haematological malignancies. Further studies of protein expression are now needed to validate these antigens as vaccine candidates.
Indexed as
Identifiers
20726502PMC2964014W2131525196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.